Medical News

RSS

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Everist Genomics, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, and is being coordinated with investigators and resources from all three Mayo Clinic sites.

21 Jan 2011

Researchers reveal how genetic mutation contributes to cancer development

Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation's discovery in 2008. The hunt is now yielding fruit. In the Jan. 18, 2011 issue of Cancer Cell, researchers reveal how the mutation contributes to cancer development and suggest potential ways to counter its effects.

21 Jan 2011

Perceived threat, rather than actual events, predict brain adaptation

A study of soldiers who took part in the ISAF mission in Afghanistan between 2008 and 2010 has found that their brains adapt when they are continuously exposed to stress. The perceived threat appears to be the major predictor of brain adaptation, rather than the actual events. In other words, if a roadside bomb goes off right in front of you, the degree to which you perceive this as threatening is what counts. This is what determines how the brain and the stress system adapt.

21 Jan 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Cancer Research UK launches new Centre in Glasgow

Cancer Research UK today (Thursday) launches a new Centre which will accelerate the pace of research in Glasgow and see the city become a world leader in the development of new treatments tailored for individual cancer patients.

21 Jan 2011

NYC Council Member introduces legislation to prohibit fluoridation of water supply

On January 18, 2011, NYC Council Member Peter Vallone, Jr. introduced legislation (Int 0463-2011) "prohibiting the addition of fluoride to the water supply

21 Jan 2011

Jiangbo Pharmaceuticals reaches settlement with debenture holders

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.

21 Jan 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California.

21 Jan 2011

PenTAG research plays pivotal role in NICE decision to extend availability of Alzheimer's disease drugs

A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced on 18th January 2011.

21 Jan 2011

SQI fourth quarter net loss increases to $2,621,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the fourth quarter and year ended September 30, 2010.

21 Jan 2011

Acetylation complex fits like a halo over a histone

To understand the emerging science of epigenetics-a field that describes how genes may be regulated without altering the underlying DNA itself-scientists are deciphering the many ways in which enzymes act on the proteins surrounding DNA within cells.

21 Jan 2011

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Intellipharmaceutics International Inc. today announced that it has received purchase agreement commitments from institutional investors to provide the Company with approximately US$12,000,000 in gross proceeds through the sale of its common stock and warrants.

21 Jan 2011

$Medicare reimbursed for only a fraction of the services recommended by government task force, study finds$

Medicare reimbursed for only a fraction of the services recommended by government task force, study finds

Health care reform should be able to mend a disconnect that has existed between the recommendations of the U.S. Preventive Services Task Force (USPSTF), a task force charged by the government to review clinical preventive health services for older adults, and Medicare coverage for those services, a new UCLA-led study finds.

21 Jan 2011

How genetic abnormalities transform normal cells into leukemic cells

Cancer scientists led by Dr. John Dick at the Ontario Cancer Institute (OCI) and collaborators at St Jude Children's Research Hospital (Memphis) have found that defective genes and the individual leukemia cells that carry them are organized in a more complex way than previously thought.

21 Jan 2011

AHF proposes funding solutions to current ADAP crisis

In anticipation of an additional round of cuts to the AIDS Drug Assistance Program (ADAP) to be implemented in the next few months, AIDS Healthcare Foundation (AHF) today proposed three possible funding solutions to the current ADAP crisis—which has left more than 5,000 people on waiting lists to receive lifesaving medications and thousands more scheduled to be disenrolled from the program altogether. Currently,

21 Jan 2011

Three million Medicare beneficiaries receive prescription drug cost relief through Affordable Care Act

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced that three million Medicare beneficiaries nationwide have received prescription drug cost relief through the Affordable Care Act. To date, three million eligible beneficiaries who fell into the drug coverage gap known as the donut hole during 2010 have been mailed a one-time, tax-free $250 rebate check.

21 Jan 2011

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

VIVUS, Inc. today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug Application (NDA) for QNEXA®, an investigational drug for the treatment of obesity. The meeting occurred on January 19th at the FDA's offices in Maryland and was attended by senior members of the FDA and VIVUS' management and consultants.

21 Jan 2011

Sunshine and Binghamton University enter research agreement for cancer compound

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).

21 Jan 2011

GSK, Valeant receive European CHMP positive opinion for Trobalt

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Trobalt™ (retigabine) as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

21 Jan 2011

Medical News

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Researchers reveal how genetic mutation contributes to cancer development

Perceived threat, rather than actual events, predict brain adaptation

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

Cancer Research UK launches new Centre in Glasgow

NYC Council Member introduces legislation to prohibit fluoridation of water supply

Jiangbo Pharmaceuticals reaches settlement with debenture holders

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

PenTAG research plays pivotal role in NICE decision to extend availability of Alzheimer's disease drugs

SQI fourth quarter net loss increases to $2,621,000

Acetylation complex fits like a halo over a histone

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Medicare reimbursed for only a fraction of the services recommended by government task force, study finds

How genetic abnormalities transform normal cells into leukemic cells

AHF proposes funding solutions to current ADAP crisis

Three million Medicare beneficiaries receive prescription drug cost relief through Affordable Care Act

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

Sunshine and Binghamton University enter research agreement for cancer compound

GSK, Valeant receive European CHMP positive opinion for Trobalt

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News